TASIGNA is now indicated for patients newly diagnosed with Ph+

Is it possible to improve on imatinib?

TASIGNA has significantly more power to reduce progression vs imatinib to AP/BC than imatinib in patients with newly diagnosed Ph+ CML.

What outcomes can I expect in imatinib-resistant or -intolerant patients?

Achieve high overall survival with TASIGNA in heavily pretreated imatinib-resistant or -intolerant patients.

Can tolerability help patients maintain therapy?

TASIGNA has a favorable tolerability profile in newly diagnosed patients.

ENESTnd 3-year publication

In adult patients with newly diagnosed Ph+ CML, more power to reduce the risk of progression vs imatinib1

Use the interactive daily planner to find the best time to fit TASIGNA into your patients' schedules

References:
1. TASIGNA® (nilotinib) Summary of Product Characteristics. Basel, Switzerland: Novartis Pharma AG; June 2014.
2. Hochhaus A, et al. Blood. 2012;120(21):Abstract 167.
3. Marin D, et al. J Clin Oncol. 2012;30(3):232-238.
4. Manley PW, et al. Biochim Biophys Acta. 2005;1754(1-2):3-13.